Analyst Emily Bodnar of H.C. Wainwright reiterated a Buy rating on Agios Pharma, reducing the price target to $48.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar has given her Buy rating due to a combination of factors related to the recent trial results and the overall safety profile of Agios Pharma’s mitapivat. The RISE UP Phase 3 trial demonstrated a significant improvement in hemoglobin response, with 40.6% of patients showing a positive outcome compared to just 2.9% in the placebo group. Although the trial did not meet the primary endpoint for reducing sickle cell pain crises, the achievement of key hemolysis endpoints and the favorable hemoglobin response are promising indicators.
Furthermore, the safety profile of mitapivat appears favorable, with no significant imbalance in adverse events compared to the placebo group, and no new safety concerns were observed. Despite some uncertainties regarding FDA approval and commercialization potential, the precedent set by Oxbryta’s approval based on similar markers provides cautious optimism. Emily Bodnar views the market’s reaction as exaggerated and maintains a Buy rating, anticipating further updates in December and early 2026.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGIO in relation to earlier this year.